Mereo Biopharma 1 Limited

Novartis Ag

Ablynx N.v.

Stefan De Buck

Jacqueline Parkin

Colm Farrell

Cyril Clarke

Colin Orford

Erik Depla

Karen Silence

Peter Vanlandschoot

Hans De Haard

Erwin Sablon

Xavier Saelens

Bert Schepens

Marie-Paule Lucienne Armanda Bouche

Mark Vaeck

Martin Kaul

Alessandra Vitaliti Garami

Sam Lindgren

Paul M P Van Bergen En Henegouwen

Souvik Bhattacharya

Bruno Bieth

Andrijana Radivojevic

Bruno Cenni

Maciej Cabanski

Arvind Kinhikar

Julian Storim

Thomas Severin

Andreas Christ

Christoph Burkhart

Christoph Kalis

Marie-Paule Lucienne Bouche

The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

The present disclosure relates to methods for treating Sjögren's Syndrome disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Sjögren's Syndrome patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor

This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease

This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of inflammatory conditions.

Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.

Pulmonary administration of immunoglobulin single variable domains and constructs thereof

Growing community of inventors

Basel, Switzerland

Stefan De Buck